Recruiting nowN/AAges 18 Years and up
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT05224934 on ClinicalTrials.gov ↗
Conditions studied
Soft Tissue SarcomaRetroperitoneal SarcomaRadiotherapy Side EffectUltra-hypofractionated RadiotherapyStereotactic Ablative Radiotherapy
What it tests
- ultra-hypofractionated radiotherapyradiation
Where it's running1 site
1 international site
- Recruiting now
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China 100021
- Ningning Lu, Doctor(contact)+86 01087787630[email protected]
- Shu-Lian Wang, M.D.(contact)+86 01087788280[email protected]
- Nian-Zeng Xing, M.D(principal investigator)
- Shu-Lian Wang, M.D(principal investigator)
- Ning-Ning Lu, M.D.(principal investigator)
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: * Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis * Sarcoma not originated from bone structure, abdominal or gynecological viscera * All disease can be included safely within one radiotherapy field * Absence of extension through the sciatic notch or across the diaphragm * Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma * ECOG performance status 0 to 2 * American Society of Anesthesiologist (ASA) score ≤2 * Normal renal function: Calculated Creatinine Clearance ≥50ml/min(by Cockcroft-Gault formula)and functional contralateral kidney by differential renal isotope scan * Normal bone marrow and hepatic function. * Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age * expected life expectancy longer than 5 years * Written consent form was given prior to treatment * Can safely be treated by radiotherapy and surgery Exclusion Criteria: * metastatic disease * Tumor was previously treated by radiotherapy * Involvement of liver, pancreatic head or duodenum
Updated 2025-12-11 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.